bearish

Remegen

Remegen (9995.HK/688331.CH) - The Survival Problem Is Becoming Imminent

390 Views08 Nov 2023 08:55
Due to “undeniable flaw” in commercialization logic, RemeGen has to face high cost/low efficiency, leading to increasing net loss.RemeGen is short of money.If financing isn't available, risks are high
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
x